Patent intelligence · US
US 11376263
Cyproterone acetate compositions and uses thereof
Cyproterone acetate compositions and uses thereof
Patent details — US 11376263
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 5, 2022
- Expiration
- Jun 30, 2042
- Applicant
- Fortress Biotech, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K31/567, A61K31/573, A61K9/0053
Quick answer
US 11376263 (Cyproterone acetate compositions and uses thereof) is held by Fortress Biotech, Inc.. Status: granted. Granted Jul 5, 2022. Expires Jun 30, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Fortress Biotech, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/567, A61K31/573, A61K9/0053, A61K9/20, A61P
Frequently asked questions
What is US patent 11376263?
US 11376263 (Cyproterone acetate compositions and uses thereof) is held by Fortress Biotech, Inc.. Status: granted. Granted Jul 5, 2022. Expires Jun 30, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11376263?
Fortress Biotech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11376263 expire?
Our index shows an expiration date of Jun 30, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.